Dr. Yao on Health-Related QOL in Patients With Neuroendocrine Tumors

Video

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, discusses a study exploring health-related quality of life (QOL) in patients with neuroendocrine tumors (NETs).

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study exploring health-related quality of life (QOL) in patients with neuroendocrine tumors (NETs).

Researchers discussed that patients with active NETs were associated with a decreased QOL. In patients whose tumors were resected and their disease was in remission, their QOL was closer to the general population. It was also found that patients with carcinoid syndrome had QOL issues impacted by their disease.

Further analyses concluded that 2 or 3 bowel movements daily had minimal impact on patient QOL. However, those with 4 or more bowel movements daily had a decreased QOL.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD